ストックスクリーナーアプリを入手
50.38
1.24%
0.60
前日終値:
$49.78
開ける：
$50
24時間の取引高:
928.09K
Relative Volume:
0.46
時価総額：
$7.85B
収益：
$1.17B
当期純損益:
$150.71M
株価収益率:
53.60
EPS:
0.94
ネットキャッシュフロー:
$245.03M
1週間 パフォーマンス:
-0.19%
1か月 パフォーマンス:
-6.80%
6か月 パフォーマンス:
-33.66%
1年 パフォーマンス:
-36.71%
1日の値動き範囲:
$49.78
$50.77
1週間の範囲:
$46.77
$51.04
52週間の値動き範囲:
$46.01
$85.57
Bio Techne Corp Stock (TECH) Company Profile
TECH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
50.39 | 7.85B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.55 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
541.65 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
556.88 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.09 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.97 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 開始されました | Evercore ISI | Outperform |
| 2025-02-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-08 | 開始されました | Scotiabank | Sector Outperform |
| 2024-02-02 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-08-28 | 開始されました | William Blair | Outperform |
| 2023-01-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-04-25 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | アップグレード | Stifel | Hold → Buy |
| 2021-01-25 | 繰り返されました | The Benchmark Company | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-07-15 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | ダウングレード | Stifel | Buy → Hold |
| 2020-05-14 | 開始されました | The Benchmark Company | Buy |
| 2020-01-08 | 再開されました | Stephens | Overweight |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Neutral |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-07-02 | アップグレード | Janney | Neutral → Buy |
| 2019-01-14 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | ダウングレード | Craig Hallum | Buy → Hold |
| 2018-10-17 | 開始されました | Goldman | Neutral |
| 2018-06-15 | 開始されました | Argus | Buy |
| 2017-07-13 | 開始されました | Wells Fargo | Market Perform |
| 2017-02-09 | 開始されました | Citigroup | Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Buy |
| 2016-11-10 | 再開されました | Leerink Partners | Outperform |
| 2015-01-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2013-09-20 | アップグレード | Robert W. Baird | Neutral → Outperform |
すべてを表示
Bio Techne Corp (TECH) 最新ニュース
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - Stock Titan
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global Challenges - GuruFocus
Bio-Techne Reports Strong Q3 2025 Revenue Growth - TipRanks
Bio-Techne’s Earnings Call: Growth Amid Challenges - TipRanks
Revolutionizing Gene Therapy Protein Expression Potency Assays - Genetic Engineering and Biotechnology News
Bio-Techne Leads Key Proteomic Reagent Markets - Morningstar
Bio-Techne exceeds profit expectations, announces new share buyback plan - MSN
Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c - TipRanks
Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges - TipRanks
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70 - marketscreener.com
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
Earnings call transcript: Bio-Techne beats Q3 2025 EPS forecasts, stock dips - Investing.com
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket - Zacks Investment Research
Bio Techne (TECH) Fell on Negative Funding Environment - Insider Monkey
Is the Options Market Predicting a Spike in BioTechne Stock? - Zacks Investment Research
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance - Investing.com Canada
Bio-Techne Board Approves Share Repurchase Program - Nasdaq
Bio-Techne Reports Q3 2025 Financial Results - TipRanks
Bio-Techne Corporation (TECH) Announces $500 Million Share Repurchase Program - GuruFocus
Bio-Techne Corp (TECH) Q3 Earnings: Adjusted EPS Surpasses Estimates at $0.56, Revenue Slightly Misses at $316.2 Million - GuruFocus
Bio-Techne earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM | TECH Stock News - GuruFocus
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS | TECH Stock News - GuruFocus
Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars - Yahoo Finance
Bio-Techne Corp. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bio-Techne Declares Dividend And New Share Repurchase Program - TradingView
Bio-Techne Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025 - marketscreener.com
Bio-Techne Earnings: Strong Growth in Protein Sciences, but US Academic Market Uncertain - Morningstar
Bio-Techne Announces New $500M Share Repurchase Program - TipRanks
Is The Options Market Predicting A Spike In BioTechne Stock? - Barchart.com
ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. - Quantisnow
Bio-Techne to Host Conference Call on May 7, 2025, to Announce T - GuruFocus
Should You Hold Bio-Techne Corp. (TECH) For the Long Term? - Insider Monkey
TECH Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
ScaleReady Announces March Biosciences as Recipient of G-Rex Grant to Advance Manufacturing of Novel CAR-T Cell Therapy - marketscreener.com
ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy - PR Newswire
Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt? - simplywall.st
Bio-Techne's Q3 2025 Earnings: What to Expect - Nasdaq
Bio-Techne's Q3 2025 Earnings: What To Expect - Barchart.com
Innovative Spatial Biology Tools - Trend Hunter
Bio-Techne Corporation (TECH) Slid Due to NIH’s Funding Concerns - Insider Monkey
Bio Techne Corp (TECH) 財務データ
収益
当期純利益
現金流量
EPS
Bio Techne Corp (TECH) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bohnen Shane | SVP - General Counsel |
Apr 03 '25 |
Option Exercise |
0.00 |
2,260 |
0 |
3,941 |
| Herr Amy E. | Director |
Feb 14 '25 |
Option Exercise |
44.33 |
1,976 |
87,596 |
3,836 |
| Herr Amy E. | Director |
Feb 14 '25 |
Sale |
65.96 |
1,860 |
122,691 |
1,976 |
2.11%
0.83%
大文字化:
|
ボリューム (24 時間):